Your browser doesn't support javascript.
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
Richardson, Simone I; Madzorera, Vimbai Sharon; Spencer, Holly; Manamela, Nelia P; van der Mescht, Mieke A; Lambson, Bronwen E; Oosthuysen, Brent; Ayres, Frances; Makhado, Zanele; Moyo-Gwete, Thandeka; Mzindle, Nonkululeko; Motlou, Thopisang; Strydom, Amy; Mendes, Adriano; Tegally, Houriiyah; de Beer, Zelda; Roma de Villiers, Talita; Bodenstein, Annie; van den Berg, Gretha; Venter, Marietjie; de Oliviera, Tulio; Ueckermann, Veronica; Rossouw, Theresa M; Boswell, Michael T; Moore, Penny L.
  • Richardson SI; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Madzorera VS; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Spencer H; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Manamela NP; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • van der Mescht MA; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
  • Lambson BE; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Oosthuysen B; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Ayres F; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Makhado Z; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Moyo-Gwete T; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Mzindle N; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Motlou T; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Strydom A; Zoonotic Arbo and Respiratory Virus Program, Centre for Viral Zoonoses, Department of Medical Virology, University of Pretoria, Pretoria, South Africa.
  • Mendes A; Zoonotic Arbo and Respiratory Virus Program, Centre for Viral Zoonoses, Department of Medical Virology, University of Pretoria, Pretoria, South Africa.
  • Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • de Beer Z; Tshwane District Hospital, Pretoria, South Africa.
  • Roma de Villiers T; Tshwane District Hospital, Pretoria, South Africa.
  • Bodenstein A; Tshwane District Hospital, Pretoria, South Africa.
  • van den Berg G; Tshwane District Hospital, Pretoria, South Africa.
  • Venter M; Zoonotic Arbo and Respiratory Virus Program, Centre for Viral Zoonoses, Department of Medical Virology, University of Pretoria, Pretoria, South Africa.
  • de Oliviera T; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa; Centre for the AIDS Programme of Research in South Africa, Durban, Sou
  • Ueckermann V; Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.
  • Rossouw TM; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
  • Boswell MT; Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.
  • Moore PL; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa; Institute of Infectious Disease and Molecular Medicine, Universi
Cell Host Microbe ; 30(6): 880-886.e4, 2022 06 08.
Article in English | MEDLINE | ID: covidwho-1889288
ABSTRACT
The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We used plasma from 20 unvaccinated and 7 vaccinated individuals infected by Omicron BA.1 to test binding, Fc effector function, and neutralization against VOCs. In unvaccinated individuals, Fc effector function and binding antibodies targeted Omicron and other VOCs at comparable levels. However, Omicron BA.1-triggered neutralization was not extensively cross-reactive for VOCs (14- to 31-fold titer reduction), and we observed 4-fold decreased titers against Omicron BA.2. In contrast, vaccination followed by breakthrough Omicron infection associated with improved cross-neutralization of VOCs with titers exceeding 12,100. This has important implications for the vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging VOCs. Although Omicron-based immunogens might be adequate boosters, they are unlikely to be superior to existing vaccines for priming in SARS-CoV-2-naive individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.03.029

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: J.chom.2022.03.029